Spots Global Cancer Trial Database for An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
Official Title: An Extension to a Phase II Open-label Study to Determine the Safety and Anti-leukemic Effects of STI571 in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Myeloid Blast Crisis
Study ID: NCT00171158
Conditions
Interventions
Study Description
Brief Summary: This extension II study allowed for further follow-up of the disease under treatment with imatinib mesylate and allow the participants to continue to receive imatinib mesylate.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Chicago, Chicago, Illinois, United States
Dana Faber Institute, Boston, Massachusetts, United States
MD Anderson Cancer Center, Houston, Texas, United States
Novartis Investigative Site, Poitiers, , France
Novartis Investigative Site, Frankfurt/Main, , Germany
Novartis Investigative Site, Leipzig, , Germany
Novartis Investigative Site, Mannheim, , Germany
Novartis Investigative Site, Muenchen, , Germany
Novartis Investigative Site, Bologna, , Italy
Novartis Investigative Site, Monza, , Italy
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
